Showing 5161-5170 of 5760 results for "".
- Is 'Mitoiron Claw' the Next Great Sunscreen Ingredient?https://practicaldermatology.com/news/is-mitoiron-claw-the-next-great-sunscreen-ingredient/2458493/A new compound that blocks excess free iron in the mitochondria may offer dramatic protection against Ultraviolet A (UVA) radiation in sunlight, according to scientists at the University of Bath and King's College London. Most sunscreens protect well against solar Ultraviolet B
- ISDIN Launches in the UShttps://practicaldermatology.com/news/isdin-launches-in-the-us/2458501/Barcelona-based ISDIN is officially operating in the US. The company—which operates in Europe, Latin America, and Asia—is bringing its skincare products to the US market. ISDIN’s portfolio of over-the-counter products target
- Some Fan-Favorite Sunscreens Don't Adhere to AAD Guidelineshttps://practicaldermatology.com/news/some-fan-favorite-sunscreens-dont-adhere-to-aad-guidelines/2458509/While consumers give rave reviews to some sunscreens, many of these products do not meet American Academy of Dermatology (AAD) guidelines, according to a new article published online by JAMA Dermatology.
- Laser Procedures Seem Generally OK for Psoriasis Patients: Analysishttps://practicaldermatology.com/news/laser-procedures-seem-generally-ok-for-psoriasis-patients-analysis/2458515/Patients with psoriasis who undergo laser procedures do not appear to be at risk for koebnerization, according to research published this spring in Dermatologic Surge
- Regenica® Rejuvenating Dual Serum Improves Skin Texture, Tone Through 90 Dayshttps://practicaldermatology.com/news/regenica-rejuvenating-dual-serum-improves-skin-texture-tone-through-90-days/2458521/New research shows that Regenica® Rejuvenating Dual Serum starts working at as early as 14 days, with continued improvement seen through 90 days. In the study, statistically significant improvements were reported as early as 14 days, wi
- New Hair Restoration Group Started for Dermatologists, Facial Plastic Surgeons and Plastic Surgeonshttps://practicaldermatology.com/news/new-hair-restoration-group-started-for-dermatologists-facial-plastic-surgeons-and-plastic-surgeons/2458525/Introducing The North American Society for Hair Restoration (NASHR), a new non-profit medical association comprising plastic surgeons, facial plastic surgeons and dermatologists who have the proper training for hair transplantation surgery.
- With $25 Million Financing, Suneva Medical Gets Ready to Up Their Gamehttps://practicaldermatology.com/news/with-25-million-financing-suneva-medical-gets-ready-to-up-their-game/2458531/Suneva Medical closed $25 million financing to support continued growth opportunities, the company reports. This financing, which includes $25 million equity investment from Essex Woodlands, strengthens Suneva Medi
- UCB: Investigational Bimekizumab Helps Psoriatic Arthritis in Phase 1Bhttps://practicaldermatology.com/news/ucb-investigational-bimekizumab-helps-psoriatic-arthritis-in-phase-1b/2458534/Bimekizumab, in development by UCB, has shown promise for the treatment of psoriatic arthritis (PsA) in Phase 1B studies. For the study, a total of 52 PsA patients inadequately controlled with at least one disease-modifying anti-rheumatic drug (DMARD) and/or one biologic were randomized to
- Dermatologist Swaps His Scalpel for a Penhttps://practicaldermatology.com/news/dermatologist-swaps-his-scalpel-for-a-pen/2458535/Steven M. Hacker, MD, a Delray Beach dermatologist and author, has released his debut novel. "The Caduceus and The Swastika". The thriller tells a frightening but endearing story of what happened to a group of medical students when Nazi's became medical professors and began a
- Pfizer/Anacor Merger To Fuel Already Robust AD Pipelinehttps://practicaldermatology.com/news/pfizeranacor-merger-fuels-already-robust-ad-pipeline/2458542/For years, there were few, if any, promising new treatments for atopic dermatitis (AD), but today the pipeline is robust, and a Pfizer-Anacor merger may help both of the companies’ pipeline candidates gain market share,